financetom
Business
financetom
/
Business
/
STMicroelectronics cuts full-year outlook for second time
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
STMicroelectronics cuts full-year outlook for second time
Jul 24, 2024 10:24 PM

July 25 (Reuters) - Franco-Italian chipmaker

STMicroelectronics (STM) on Thursday cut its

full-year revenues guidance for the second time this year as

industrial customer orders did not improve and automotive demand

declined.

The company, whose clients include Tesla and Apple ( AAPL )

, said it expects revenue in the range of $13.2 billion

to $13.7 billion for 2024, against a previous forecast range of

$14 billion to $15 billion.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Infosys Expands AI Collaboration With Microsoft
Infosys Expands AI Collaboration With Microsoft
Oct 10, 2024
07:15 AM EDT, 10/09/2024 (MT Newswires) -- Infosys ( INFY ) said Wednesday that it has expanded its collaboration with Microsoft ( MSFT ) to accelerate their customers' adoption of Microsoft Azure and generative artificial intelligence. Infosys ( INFY ) said the collaboration allows the company to integrate Microsoft's ( MSFT ) generative AI offerings across its Solution IP portfolio....
BMO Comments on New Zealand's Central Bank Cutting Key Rate by 50bps
BMO Comments on New Zealand's Central Bank Cutting Key Rate by 50bps
Oct 10, 2024
07:44 AM EDT, 10/09/2024 (MT Newswires) -- The Reserve Bank of New Zealand kicked its easing campaign into high gear on Wednesday, lowering the official cash rate by 50 bps to 4.75%, noted Bank of Montreal (BMO). On the growth outlook, the RBNZ said Economic activity in New Zealand is subdued, in part due to restrictive monetary policy. Business investment...
Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data
Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data
Oct 10, 2024
07:16 AM EDT, 10/09/2024 (MT Newswires) -- Clearside Biomedical ( CLSD ) shares were up more than 26% in Wednesday's premarket activity after the company said its topline data from its phase 2b clinical trial of CLS-AX for the treatment of neovascular age-related macular degeneration showed the drug achieved both primary and secondary outcomes. Among 60 participants in the trial...
Helen of Troy's Fiscal Q2 Adjusted Earnings, Net Sales Fall; 2025 Guidance Reaffirmed
Helen of Troy's Fiscal Q2 Adjusted Earnings, Net Sales Fall; 2025 Guidance Reaffirmed
Oct 10, 2024
07:15 AM EDT, 10/09/2024 (MT Newswires) -- Helen of Troy (HELE) reported fiscal Q2 adjusted earnings Wednesday of $1.21 per diluted share, down from $1.74 a year earlier. Analysts polled by Capital IQ expected $1.05. Net sales for the quarter ended Aug. 31 were $474.2 million, compared with $491.6 million a year earlier. Analysts surveyed by Capital IQ expected $458.9...
Copyright 2023-2025 - www.financetom.com All Rights Reserved